Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Aug 04, 2011, 05:09 ET from Reportlinker

NEW YORK, Aug. 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

http://www.reportlinker.com/p0587643/Lung-Cancer-A-Decision-Support-Tool-for-Optimizing-the-Pipeline-from-Research-To-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

This report comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 217 companies, from Ceased to Marketed. The report extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and three subindications of lung cancer. BioSeeker has applied its unique drug assessment methodology to stratify the lung cancer pipeline and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of lung cancer drugs is split between the 43% which have unique drug target strategies and the other part which have head-to-head target competing lung cancer drugs in 58 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the lung cancer drugs in general. Contributing to this fact is heavily utilized drug target strategies like: TUBB, TOP2A and TOP1.

* Nine out of ten drug target strategies in Phase II development are new to lung cancer drugs and the greatest numbers of new target strategies are found in Phase II (39%) and Phase I development (17%).

* Small molecules, antibodies and reformulated drugs are the dominating compound strategies of lung cancer drugs, which represent almost 80% of the entire pipeline. Cell therapy based lung cancer drugs has the lowest representation in the defined target strategy portfolio compared to that of other compound strategies of lung cancer drugs.

* Peptide based lung cancer drugs has a 50% drug target strategy overlap with all other compound strategies, especially with that of antibodies, small molecules and reformulated compound strategies.

* The highest number of described drug target strategies of lung cancer drugs belongs to Pfizer (15), Bristol-Myers Squibb (11) and Hoffmann-La Roche (11).

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any lung cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.

Table of Contents

1 Executive Summary 3

2 About Cancer Highlights™ 5

2.1 Cancer Focus Areas 5

2.2 Subscribe Today and Start Saving 6

2.2.1 Type of License 6

2.3 Additional Information 6

2.4 BioSeeker Group's Oncology Team 6

3 Methodology 7

3.1 Cancer Highlights'™ Five Pillar Drug Assessment 7

4 Table of Contents 9

4.1 List of Figures 22

4.2 List of Tables 22

5 Introduction 31

5.1 The Scope of this Report 31

5.2 Definitions 34

5.3 Abbreviations 34

6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment 35

6.1 Drug Repositioning in Oncology 35

6.2 Introduction to Targets of Lung Cancer Drugs 36

6.2.1 Auxiliary Transport Protein Activity Targets 44

6.2.2 Carboxy-lyase Activity Targets 45

6.2.3 Catalytic Activity Targets 46

6.2.4 Cell Adhesion Molecule Activity Targets 52

6.2.5 Chaperone Activity Targets 63

6.2.6 Chemokine Activity Targets 67

6.2.7 Complement Activity Targets 70

6.2.8 Cysteine-type Peptidase Activity Targets 71

6.2.9 Cytokine Activity Targets 78

6.2.10 DNA Binding Targets 87

6.2.11 DNA Repair Protein Targets 90

6.2.12 DNA Topoisomerase Activity Targets 93

6.2.13 DNA-directed DNA Polymerase Activity Targets 99

6.2.14 DNA-methyltransferase Activity Targets 106

6.2.15 Extracellular Ligand-gated Ion Channel Activity Targets 107

6.2.16 Extracellular Matrix Structural Constituent Targets 109

6.2.17 G-protein Coupled Receptor Activity Targets 112

6.2.18 Glutathione Transferase Activity Targets 122

6.2.19 Growth Factor Activity Targets 124

6.2.20 GTPase Activity Targets 138

6.2.21 Hormone Activity Targets 147

6.2.22 Hydrolase Activity Targets 149

6.2.23 Intracellular Ligand-gated Ion Channel Activity Targets 150

6.2.24 Ion Channel Activity Targets 151

6.2.25 Kinase Activity Targets 152

6.2.26 Kinase Binding Targets 163

6.2.27 Kinase Regulator Activity Targets 164

6.2.28 Ligand-dependent Nuclear Receptor Activity Targets 167

6.2.29 Ligase Activity Targets 173

6.2.30 Lipid Kinase Activity Targets 180

6.2.31 Lipid Phosphatase Activity Targets 188

6.2.32 Metallopeptidase Activity Targets 189

6.2.33 Molecular Function Unknown Targets 194

6.2.34 Motor Activity Targets 202

6.2.35 Oxidoreductase Activity Targets 204

6.2.36 Peptidase Activity Targets 209

6.2.37 Peroxidase Activity Targets 219

6.2.38 Phosphoric Diester Hydrolase Activity Targets 220

6.2.39 Protein Binding Targets 223

6.2.40 Protein Serine/Threonine Kinase Activity Targets 228

6.2.41 Protein Threonine/Tyrosine Kinase Activity Targets 259

6.2.42 Protein Threonine/Tyrosine Kinase Activity Targets 264

6.2.43 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 265

6.2.44 Protein-tyrosine Kinase Activity Targets 266

6.2.45 Receptor Activity Targets 279

6.2.46 Receptor Binding Targets 302

6.2.47 Receptor Signaling Complex Scaffold Activity Targets 310

6.2.48 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 315

6.2.49 RNA Binding Targets 317

6.2.50 RNA-directed DNA Polymerase Activity Targets 318

6.2.51 Serine-type Peptidase Activity Targets 320

6.2.52 Structural Constituent of Cytoskeleton Targets 324

6.2.53 Structural Molecule Activity Targets 328

6.2.54 Transcription Factor Activity Targets 330

6.2.55 Transcription Regulator Activity Targets 360

6.2.56 Transferase Activity Targets 368

6.2.57 Translation Regulator Activity Targets 370

6.2.58 Transmembrane Receptor Activity Targets 376

6.2.59 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 380

6.2.60 Transporter Activity Targets 422

6.2.61 Ubiquitin-specific Protease Activity Targets 430

6.2.62 Other Targets 432

6.3 The Cancer Genome Project and Targets of Lung Cancer Drugs 434

6.3.1 Targets of Lung Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 434

6.4 Structure-based Drug Design in Lung Cancer Therapeutics is Stimulated by Available Structure Data on Biological Targets 441

6.5 Target-Target Interactions among Identified Targets of Lung Cancer Drugs 446

6.6 The Drug-Target Competitive Landscape 451

6.7 Protein Expression Levels of Identified Targets of Lung Cancer Drugs 456

6.8 Pathway Assessment of Lung Cancer Drugs 459

6.8.1 Tools for Analysis of Cancer Pathways 460

6.8.2 Pathway Assessment 461

7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development 527

7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Lung Cancer Drugs 531

7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Lung Cancer Drugs 533

7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Lung Cancer Drugs 536

7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Lung Cancer Drugs 544

7.5 Preclinical Development: New and Unique Drug Target Strategies of Lung Cancer Drugs 549

7.6 Drug Target Strategies of Suspended or Terminated Lung Cancer Drugs 553

7.7 Target Strategy Development Profiles of Lung Cancer Drugs 558

7.7.1 Marketed 564

7.7.2 Phase III 579

7.7.3 Phase II 599

7.7.4 Phase I 693

7.7.5 Preclinical 733

7.7.6 Suspended 763

7.7.7 Ceased 766

7.8 The Competition Through Close Mechanistic Approximation of Lung Cancer Drugs 809

8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy 818

8.1 Small Molecules 820

8.1.1 Background 820

8.1.2 Target Strategies of Small Molecule Drugs 821

8.2 Peptide & Protein Drugs 835

8.2.1 Background 835

8.2.2 Target Strategies of Peptide and Protein Drugs 836

8.3 Antibodies 842

8.3.1 Background 842

8.3.2 Target Strategies of Antibody Drugs 842

8.4 Nucleic Acid Therapies 848

8.4.1 Background 848

8.4.2 Target Strategies of Nucleic Acid Drugs 849

8.5 Cell & Gene Therapy 852

8.5.1 Background 852

8.5.2 Target Strategies of Cell and Gene Therapy Drugs 853

8.6 Drug Delivery and Nanotechnology 858

8.6.1 Background 858

8.6.2 Target Strategies of Reformulated Drugs 858

8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 862

9 Selecting Subindication for Lung Cancer Drugs 871

9.1 NSCLC 872

9.2 SCLC 889

9.3 Lung Cancer (LC) 894

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator 899

10.1 Competitive Fall-Out Assessment 899

10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 901

10.3 A&G Pharmaceutical 902

10.4 Abbott 903

10.5 Active Biotech 906

10.6 Adherex 907

10.7 Advanomics 908

10.8 Advantagene 910

10.9 AEgera 911

10.10 AEterna Zentaris 912

10.11 Agennix 913

10.12 Aida Pharmaceuticals 914

10.13 Alchemia 915

10.14 Alder Biopharmaceuticals 917

10.15 Alethia Biotherapeutics 918

10.16 Allos Therapeutics 919

10.17 AlphaVax 920

10.18 Altor BioScience 921

10.19 Amgen 922

10.20 AngioChem 928

10.21 Antisense Pharma 930

10.22 Antisoma 931

10.23 Anza Therapeutics 932

10.24 ApopLogic Pharmaceuticals 933

10.25 Apotex 935

10.26 Ariad 936

10.27 ArQule 938

10.28 Array BioPharma 940

10.29 Ascenta Therapeutics 942

10.30 Astellas 943

10.31 AstraZeneca 946

10.32 AVEO 951

10.33 Avila Therapeutics 952

10.34 Axelar 954

10.35 Bayer 955

10.36 Benitec 959

10.37 Betapharma 960

10.38 Biogen Idec 962

10.39 Biokine Therapeutics 965

10.40 BioLineRx 966

10.41 BioNumerik 967

10.42 BioSante 969

10.43 Boehringer Ingelheim 970

10.44 Bristol-Myers Squibb 973

10.45 BTG 984

10.46 Calando Pharmaceuticals 986

10.47 CanBas 987

10.48 Celator Pharmaceuticals 988

10.49 Celgene 990

10.50 Cell Therapeutics 993

10.51 Celtic Pharma 996

10.52 Center of Molecular Immunology 997

10.53 Cephalon 999

10.54 CG Therapeutics 1002

10.55 Chemokine Therapeutics 1003

10.56 Chong Kun Dang 1004

10.57 Circadian Technologies 1007

10.58 Clavis Pharma 1008

10.59 CLL Pharma 1009

10.60 Coronado Biosciences 1012

10.61 Critical Outcome Technologies 1014

10.62 Curaxis 1015

10.63 Curis 1016

10.64 Cyclacel 1018

10.65 Cynvec 1019

10.66 CytImmune Sciences 1020

10.67 Cytokinetics 1021

10.68 CytRx 1023

10.69 Daiichi Sankyo 1025

10.70 Dainippon Sumitomo Pharma 1030

10.71 Dara Biosciences 1033

10.72 Dendreon 1034

10.73 Dong-A 1036

10.74 ECI 1038

10.75 Eisai 1039

10.76 Elara Pharmaceuticals 1043

10.77 Eli Lilly 1046

10.78 Endocyte 1052

10.79 EntreMed 1054

10.80 EpiCept 1055

10.81 Exelixis 1057

10.82 Fresenius 1062

10.83 Galapagos 1064

10.84 Gemin X Biotechnologies 1065

10.85 Genmab 1066

10.86 Genta 1068

10.87 GenVec 1069

10.88 Genzyme 1070

10.89 Geron 1071

10.90 Gilead Sciences 1073

10.91 GlaxoSmithKline 1075

10.92 GlobeImmune 1079

10.93 GlycoGenesys 1080

10.94 Gradalis 1081

10.95 Hanmi 1082

10.96 Hoffmann-La Roche 1083

10.97 Human Genome Sciences 1091

10.98 Idera Pharmaceuticals 1092

10.99 ImmunoCellular Therapeutics 1093

10.100 Immunocore 1094

10.101 ImmunoGen 1096

10.102 Immunomedics 1099

10.103 ImmuPharma 1103

10.104 Incyte Corporation 1104

10.105 Infinity Pharmaceuticals 1105

10.106 Innovive 1106

10.107 Inovio 1107

10.108 Insys Therapeutics 1108

10.109 Intezyne Technologies 1111

10.110 Introgen Therapeutics 1113

10.111 Ipsen 1115

10.112 Isis Pharmaceuticals 1117

10.113 Jennerex Biotherapeutics 1119

10.114 Johnson & Johnson 1120

10.115 Kiadis 1123

10.116 Kyowa Hakko Kirin 1124

10.117 Ligand 1128

10.118 Lorus Therapeutics 1129

10.119 MacroGenics 1131

10.120 Marillion Pharmaceuticals 1132

10.121 Meda 1133

10.122 MediGene 1134

10.123 Medisyn Technologies 1136

10.124 Menarini 1138

10.125 Merck & Co 1140

10.126 Merck KGaA 1143

10.127 Merrimack 1147

10.128 Mersana Therapeutics 1148

10.129 MethylGene 1150

10.130 Micromet 1152

10.131 Mirna Therapeutics 1154

10.132 MolMed 1155

10.133 Mologen 1157

10.134 Mycenax 1159

10.135 Nektar Therapeutics 1160

10.136 Nereus Pharmaceuticals 1162

10.137 Nerviano Medical Sciences 1163

10.138 Neurocrine Biosciences 1165

10.139 NewSouth Innovations 1166

10.140 Nippon Kayaku 1167

10.141 Nippon Shinyaku 1169

10.142 Non-industrial Source 1170

10.143 Novacea 1171

10.144 Novartis 1172

10.145 Oasmia 1178

10.146 OncoGenex Pharmaceuticals 1180

10.147 OncoMed 1182

10.148 Oncothyreon 1183

10.149 Orchestra Therapeutics 1185

10.150 OSI Pharmaceuticals 1186

10.151 OXiGENE 1189

10.152 Paladin Labs 1190

10.153 PanaGin 1191

10.154 PBL Therapeutics 1192

10.155 Pfizer 1193

10.156 Pharmacyclics 1202

10.157 PharmaGap 1203

10.158 PharmaMar 1204

10.159 Pharmexa 1207

10.160 Philogen 1208

10.161 Pierre Fabre 1210

10.162 Pro-Pharmaceuticals 1211

10.163 Progen Pharmaceuticals 1212

10.164 Receptor BioLogix 1213

10.165 Regeneron 1214

10.166 Regulon 1215

10.167 RESprotect 1216

10.168 Rexahn 1217

10.169 Rigel 1219

10.170 Samyang 1221

10.171 Sanofi-Aventis 1225

10.172 Sareum 1229

10.173 Seattle Genetics 1231

10.174 ShimodaAtlantic Oncology 1232

10.175 Shire 1233

10.176 Sigma-Tau 1234

10.177 Silence Therapeutics 1236

10.178 Simcere Pharmaceuticals 1237

10.179 Sirnaomics 1238

10.180 SRI International 1239

10.181 SuperGen 1240

10.182 Supratek Pharma 1243

10.183 Switch Pharma 1247

10.184 Symphogen 1248

10.185 SynDevRx 1249

10.186 Synta Pharmaceuticals 1251

10.187 Taiho 1252

10.188 Takeda 1254

10.189 Talon Therapeutics 1256

10.190 Tapestry Pharmaceuticals 1257

10.191 Taxolog 1259

10.192 Tekmira Pharmaceuticals 1262

10.193 Telik 1264

10.194 Thallion Pharmaceuticals 1265

10.195 Therion Biologics 1266

10.196 Theryte 1267

10.197 Titan Pharmaceuticals 1268

10.198 TopoTarget 1270

10.199 Tracon Pharmaceuticals 1271

10.200 Tragara Pharmaceuticals 1272

10.201 Transgene 1273

10.202 TriAct Therapeutics 1275

10.203 Trion Pharma 1276

10.204 UCB 1277

10.205 Valeant 1278

10.206 Vaxon Biotech 1279

10.207 VaxOnco 1280

10.208 Vernalis 1281

10.209 Vertex Pharmaceuticals 1282

10.210 Vical 1283

10.211 Vion Pharmaceuticals 1284

10.212 VioQuest Pharmaceuticals 1286

10.213 Wilex 1287

10.214 Wyeth 1288

10.215 Xerion 1289

10.216 Xoma 1291

10.217 Yakult Honsha 1292

10.218 YM BioSciences 1294

10.219 Zhejiang Beta Pharma 1296

10.220 Zivena 1298

11 Disclaimer 1300

12 Drug Index 1301

13 Company Index 1314

List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Lung Cancer Drugs 450

Figure 2: The Drug-Target Competitive Landscape of Lung Cancer Drugs - Large Cluster 452

Figure 3: The Drug-Target Competitive Landscape Lung Cancer Drugs - Smaller Clusters 453

Figure 4: Head-to-Head Targeting Competitive Landscape of Lung Cancer Drugs - Large Clusters 454

Figure 5: Head-to-Head Targeting Competitive Landscape of Lung Cancer Drugs - Smaller Clusters 455

Figure 6: Distribution of Compound Strategies among Lung Cancer Drugs 862

Figure 7: Primary Sub-cellular Localization of Drug Targets 863

List of Tables

Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7

Table 2: Breakdown of the Included Lung Cancer Drug Pipeline by Stage of Development 31

Table 3: Head to Head Target Competition among Lung Cancer Drugs 31

Table 4: Overview of Drug Target Strategy Themes 36

Table 5: Terminally Ceased Targets of Lung Cancer Drugs 37

Table 6: Official Gene Name to Target Profle 38

Table 7: Targets of Lung Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 435

Table 8: Identity of Lung Cancer Drug Targets with Available Biological Structures 441

Table 9: Number of Target-Target Interactions among Targets of Lung Cancer Drugs 447

Table 10: Available Protein Expression Profiles of Lung Cancer Drugs Targets 456

Table 11: Pathway Summary 461

Table 12: Drug Targets without any Identified Assigned Pathways 461

Table 13: Pathway Profiles According to BioCarta of Lung Cancer Drug Targets 463

Table 14: Pathway Profiles According to KEGG of Lung Cancer Drug Targets 489

Table 15: Pathway Profiles According to NetPath of Lung Cancer Drug Targets 518

Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 527

Table 17: Top Competitive Target Strategies of Lung Cancer Drugs 528

Table 18: New and Unique Target Strategies of Pre-registration and Marketed Lung Cancer Drugs 531

Table 19: The Competition Through Close Mechanistic Approximation Between Lung Cancer Drugs being Marketed or in Pre-registration 532

Table 20: New and Unique Target Strategies in Phase III Clinical Development of Lung Cancer Drugs 533

Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Lung Cancer Drugs 534

Table 22: New and Unique Target Strategies in Phase II Clinical Development of Lung Cancer Drugs 536

Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Lung Cancer Drugs 541

Table 24: New and Unique Target Strategies in Phase I Clinical Development of Lung Cancer Drugs 544

Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Lung Cancer Drugs 547

Table 26: New and Unique Target Strategies in Preclinical Development of Lung Cancer Drugs 549

Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Lung Cancer Drugs 551

Table 28: Target Strategies of Suspended and Terminated Lung Cancer Drugs 553

Table 29: Connecting Target Strategy with Its Profile Identification Number 558

Table 30: The Competition Through Close Mechanistic Approximation Among Lung Cancer Drugs 809

Table 31: Overview of Compound Strategy Competition Among Lung Cancer Drugs 819

Table 32: Overview of the Competitive Landscape of Small Molecule Based Lung Cancer Drugs 821

Table 33: Competitive Comparison of Target Strategies of Small Molecule Lung Cancer Drugs 822

Table 34: Pursued Target Strategies of Small Molecule Drugs Based Lung Cancer Drugs 827

Table 35: Overview of the Competitive Landscape of Peptide Based Lung Cancer Drugs 836

Table 36: Competitive Comparison of Target Strategies of Peptide Based Lung Cancer Drugs 837

Table 37: Pursued Target Strategies of Peptide Based Lung Cancer Drugs 837

Table 38: Overview of the Competitive Landscape of Protein Based Lung Cancer Drugs 839

Table 39: Competitive Comparison of Target Strategies of Protein Based Lung Cancer Drugs 840

Table 40: Pursued Target Strategies of Protein Based Lung Cancer Drugs 840

Table 41: Overview of the Competitive Landscape of Antibody Based Lung Cancer Drugs 842

Table 42: Competitive Comparison of Target Strategies of Antibody Based Lung Cancer Drugs 843

Table 43: Pursued Target Strategies of Antibody Based Lung Cancer Drugs 845

Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Lung Cancer Drugs 849

Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Lung Cancer Drugs 850

Table 46: Pursued Target Strategies of Nucleic Acid Based Lung Cancer Drugs 850

Table 47: Potential Forms of Cell Therapy 852

Table 48: Vectors in Gene Therapy 853

Table 49: Overview of the Competitive Landscape of Cell Therapy Based Lung Cancer Drugs 853

Table 50: Pursued Target Strategies of Cell Therapy Based Lung Cancer Drugs 854

Table 51: Overview of the Competitive Landscape of Gene Therapy Based Lung Cancer Drugs 855

Table 52: Competitive Comparison of Target Strategies of Gene Therapy Based Lung Cancer Drugs 856

Table 53: Pursued Target Strategies of Gene Therapy Based Lung Cancer Drugs 856

Table 54:Overview of the Competitive Landscape of Reformulated Lung Cancer Drugs 858

Table 55: Competitive Comparison of Target Strategies of Reformulated Lung Cancer Drugs 859

Table 56: Pursued Target Strategies of Reformulated Lung Cancer Drugs 860

Table 57: Compound Strategies based on Sub-Cellular Localization of Lung Cancer Drug Targets 863

Table 58 Competitive Summary by Subindication of Lung Cancer Drugs 871

Table 59: Target Strategy Development Profiles of Drugs for the Treatment of NSCLC 872

Table 60: The Competition through Close Mechanistic Approximation between NSCLC Drugs 882

Table 61: Target Strategy Development Profiles of Drugs for the Treatment of SCLC 889

Table 62: The Competition through Close Mechanistic Approximation between SCLC Drugs 892

Table 63: Target Strategy Development Profiles of Drugs for the Treatment of Lung Cancer (LC) 894

Table 64: The Competition through Close Mechanistic Approximation between Lung Cancer (LC) Drugs 897

Table 65: Example of a Competitive Fall-Out Table (Targeting TUBB) 900

Table 66: Summary Table of Corporate Changes in the Competitive Landscape of Lung Cancer Drug Development 901

Table 67: A&G Pharmaceutical's Included Lung Cancer Pipeline and Competitive Fall-Out 902

Table 68: Abbott's Included Lung Cancer Pipeline and Competitive Fall-Out 903

Table 69: Active Biotech's Included Lung Cancer Pipeline and Competitive Fall-Out 906

Table 70: Adherex's Included Lung Cancer Pipeline and Competitive Fall-Out 907

Table 71: Advanomics'Included Lung Cancer Pipeline and Competitive Fall-Out 908

Table 72: Advantagene's Included Lung Cancer Pipeline and Competitive Fall-Out 910

Table 73: AEgera's Included Lung Cancer Pipeline and Competitive Fall-Out 911

Table 74: AEterna Zentaris'Included Lung Cancer Pipeline and Competitive Fall-Out 912

Table 75: Agennix's Included Lung Cancer Pipeline and Competitive Fall-Out 913

Table 76: Aida Pharmaceuticals'Included Lung Cancer Pipeline and Competitive Fall-Out 914

Table 77: Alchemia's Included Lung Cancer Pipeline and Competitive Fall-Out 915

Table 78: Alder Biopharmaceuticals'Included Lung Cancer Pipeline and Competitive Fall-Out 917

Table 79: Alethia Biotherapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 918

Table 80: Allos Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 919

Table 81: AlphaVax's Included Lung Cancer Pipeline and Competitive Fall-Out 920

Table 82: Altor BioScience's Included Lung Cancer Pipeline and Competitive Fall-Out 921

Table 83: Amgen's Included Lung Cancer Pipeline and Competitive Fall-Out 922

Table 84: AngioChem's Included Lung Cancer Pipeline and Competitive Fall-Out 928

Table 85: Antisense Pharma's Included Lung Cancer Pipeline and Competitive Fall-Out 930

Table 86: Antisoma's Included Lung Cancer Pipeline and Competitive Fall-Out 931

Table 87: Anza Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 932

Table 88: ApopLogic Pharmaceuticals'Included Lung Cancer Pipeline and Competitive Fall-Out 933

Table 89: Apotex's Included Lung Cancer Pipeline and Competitive Fall-Out 935

Table 90: Ariad's Included Lung Cancer Pipeline and Competitive Fall-Out 936

Table 91: ArQule's Included Lung Cancer Pipeline and Competitive Fall-Out 938

Table 92: Array BioPharma's Included Lung Cancer Pipeline and Competitive Fall-Out 940

Table 93: Ascenta Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 942

Table 94: Astellas'Included Lung Cancer Pipeline and Competitive Fall-Out 943

Table 95: AstraZeneca's Included Lung Cancer Pipeline and Competitive Fall-Out 946

Table 96: AVEO's Included Lung Cancer Pipeline and Competitive Fall-Out 951

Table 97: Avila Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 952

Table 98: Axelar's Included Lung Cancer Pipeline and Competitive Fall-Out 954

Table 99: Bayer's Included Lung Cancer Pipeline and Competitive Fall-Out 955

Table 100: Benitec's Included Lung Cancer Pipeline and Competitive Fall-Out 959

Table 101: Betapharma's Included Lung Cancer Pipeline and Competitive Fall-Out 960

Table 102: Biogen Idec's Included Lung Cancer Pipeline and Competitive Fall-Out 962

Table 103: Biokine Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 965

Table 104: BioLineRx's Included Lung Cancer Pipeline and Competitive Fall-Out 966

Table 105: BioNumerik's Included Lung Cancer Pipeline and Competitive Fall-Out 967

Table 106: BioSante's Included Lung Cancer Pipeline and Competitive Fall-Out 969

Table 107: Boehringer Ingelheim's Included Lung Cancer Pipeline and Competitive Fall-Out 970

Table 108: Bristol-Myers Squibb's Included Lung Cancer Pipeline and Competitive Fall-Out 973

Table 109: BTG's Included Lung Cancer Pipeline and Competitive Fall-Out 984

Table 110: Calando Pharmaceuticals'Included Lung Cancer Pipeline and Competitive Fall-Out 986

Table 111: CanBas'Included Lung Cancer Pipeline and Competitive Fall-Out 987

Table 112: Celator Pharmaceuticals'Included Lung Cancer Pipeline and Competitive Fall-Out 988

Table 113: Celgene's Included Lung Cancer Pipeline and Competitive Fall-Out 990

Table 114: Cell Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 993

Table 115: Celtic Pharma's Included Lung Cancer Pipeline and Competitive Fall-Out 996

Table 116: Center of Molecular Immunology's Included Lung Cancer Pipeline and Competitive Fall-Out 997

Table 117: Cephalon's Included Lung Cancer Pipeline and Competitive Fall-Out 999

Table 118: CG Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 1002

Table 119: Chemokine Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 1003

Table 120: Chong Kun Dang's Included Lung Cancer Pipeline and Competitive Fall-Out 1004

Table 121: Circadian Technologies'Included Lung Cancer Pipeline and Competitive Fall-Out 1007

Table 122: Clavis Pharma's Included Lung Cancer Pipeline and Competitive Fall-Out 1008

Table 123: CLL Pharma's Included Lung Cancer Pipeline and Competitive Fall-Out 1009

Table 124: Coronado Biosciences'Included Lung Cancer Pipeline and Competitive Fall-Out 1012

Table 125: Critical Outcome Technologies'Included Lung Cancer Pipeline and Competitive Fall-Out 1014

Table 126: Curaxis'Included Lung Cancer Pipeline and Competitive Fall-Out 1015

Table 127: Curis'Included Lung Cancer Pipeline and Competitive Fall-Out 1016

Table 128: Cyclacel's Included Lung Cancer Pipeline and Competitive Fall-Out 1018

Table 129: Cynvec's Included Lung Cancer Pipeline and Competitive Fall-Out 1019

Table 130: CytImmune Sciences'Included Lung Cancer Pipeline and Competitive Fall-Out 1020

Table 131: Cytokinetics'Included Lung Cancer Pipeline and Competitive Fall-Out 1021

Table 132: CytRx's Included Lung Cancer Pipeline and Competitive Fall-Out 1023

Table 133: Daiichi Sankyo's Included Lung Cancer Pipeline and Competitive Fall-Out 1025

Table 134: Dainippon Sumitomo Pharma's Included Lung Cancer Pipeline and Competitive Fall-Out 1030

Table 135: Dara Biosciences'Included Lung Cancer Pipeline and Competitive Fall-Out 1033

Table 136: Dendreon's Included Lung Cancer Pipeline and Competitive Fall-Out 1034

Table 137: Dong-A's Included Lung Cancer Pipeline and Competitive Fall-Out 1036

Table 138: ECI's Included Lung Cancer Pipeline and Competitive Fall-Out 1038

Table 139: Eisai's Included Lung Cancer Pipeline and Competitive Fall-Out 1039

Table 140: Elara Pharmaceuticals'Included Lung Cancer Pipeline and Competitive Fall-Out 1043

Table 141: Eli Lilly's Included Lung Cancer Pipeline and Competitive Fall-Out 1046

Table 142: Endocyte's Included Lung Cancer Pipeline and Competitive Fall-Out 1052

Table 143: EntreMed's Included Lung Cancer Pipeline and Competitive Fall-Out 1054

Table 144: EpiCept's Included Lung Cancer Pipeline and Competitive Fall-Out 1055

Table 145: Exelixis'Included Lung Cancer Pipeline and Competitive Fall-Out 1057

Table 146: Fresenius'Included Lung Cancer Pipeline and Competitive Fall-Out 1062

Table 147: Galapagos'Included Lung Cancer Pipeline and Competitive Fall-Out 1064

Table 148: Gemin X Biotechnologies'Included Lung Cancer Pipeline and Competitive Fall-Out 1065

Table 149: Genmab's Included Lung Cancer Pipeline and Competitive Fall-Out 1066

Table 150: Genta's Included Lung Cancer Pipeline and Competitive Fall-Out 1068

Table 151: GenVec's Included Lung Cancer Pipeline and Competitive Fall-Out 1069

Table 152: Genzyme's Included Lung Cancer Pipeline and Competitive Fall-Out 1070

Table 153: Geron's Included Lung Cancer Pipeline and Competitive Fall-Out 1071

Table 154: Gilead Sciences'Included Lung Cancer Pipeline and Competitive Fall-Out 1073

Table 155: GlaxoSmithKline's Included Lung Cancer Pipeline and Competitive Fall-Out 1075

Table 156: GlobeImmune's Included Lung Cancer Pipeline and Competitive Fall-Out 1079

Table 157: GlycoGenesys'Included Lung Cancer Pipeline and Competitive Fall-Out 1080

Table 158: Gradalis'Included Lung Cancer Pipeline and Competitive Fall-Out 1081

Table 159: Hanmi's Included Lung Cancer Pipeline and Competitive Fall-Out 1082

Table 160: Hoffmann-La Roche's Included Lung Cancer Pipeline and Competitive Fall-Out 1083

Table 161: Human Genome Sciences'Included Lung Cancer Pipeline and Competitive Fall-Out 1091

Table 162: Idera Pharmaceuticals'Included Lung Cancer Pipeline and Competitive Fall-Out 1092

Table 163: ImmunoCellular Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 1093

Table 164: Immunocore's Included Lung Cancer Pipeline and Competitive Fall-Out 1094

Table 165: ImmunoGen's Included Lung Cancer Pipeline and Competitive Fall-Out 1096

Table 166: Immunomedics'Included Lung Cancer Pipeline and Competitive Fall-Out 1099

Table 167: ImmuPharma's Included Lung Cancer Pipeline and Competitive Fall-Out 1103

Table 168: Incyte Corporation's Included Lung Cancer Pipeline and Competitive Fall-Out 1104

Table 169: Infinity Pharmaceuticals'Included Lung Cancer Pipeline and Competitive Fall-Out 1105

Table 170: Innovive's Included Lung Cancer Pipeline and Competitive Fall-Out 1106

Table 171: Inovio's Included Lung Cancer Pipeline and Competitive Fall-Out 1107

Table 172: Insys Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 1108

Table 173: Intezyne Technologies'Included Lung Cancer Pipeline and Competitive Fall-Out 1111

Table 174: Introgen Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 1113

Table 175: Ipsen's Included Lung Cancer Pipeline and Competitive Fall-Out 1115

Table 176: Isis Pharmaceuticals'Included Lung Cancer Pipeline and Competitive Fall-Out 1117

Table 177: Jennerex Biotherapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 1119

Table 178: Johnson & Johnson's Included Lung Cancer Pipeline and Competitive Fall-Out 1120

Table 179: Kiadis'Included Lung Cancer Pipeline and Competitive Fall-Out 1123

Table 180: Kyowa Hakko Kirin's Included Lung Cancer Pipeline and Competitive Fall-Out 1124

Table 181: Ligand's Included Lung Cancer Pipeline and Competitive Fall-Out 1128

Table 182: Lorus Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 1129

Table 183: MacroGenics'Included Lung Cancer Pipeline and Competitive Fall-Out 1131

Table 184: Marillion Pharmaceuticals'Included Lung Cancer Pipeline and Competitive Fall-Out 1132

Table 185: Meda's Included Lung Cancer Pipeline and Competitive Fall-Out 1133

Table 186: MediGene's Included Lung Cancer Pipeline and Competitive Fall-Out 1134

Table 187: Medisyn Technologies'Included Lung Cancer Pipeline and Competitive Fall-Out 1136

Table 188: Menarini's Included Lung Cancer Pipeline and Competitive Fall-Out 1138

Table 189: Merck & Co's Included Lung Cancer Pipeline and Competitive Fall-Out 1140

Table 190: Merck KGaA's Included Lung Cancer Pipeline and Competitive Fall-Out 1143

Table 191: Merrimack's Included Lung Cancer Pipeline and Competitive Fall-Out 1147

Table 192: Mersana Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 1148

Table 193: MethylGene's Included Lung Cancer Pipeline and Competitive Fall-Out 1150

Table 194: Micromet's Included Lung Cancer Pipeline and Competitive Fall-Out 1152

Table 195: Mirna Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 1154

Table 196: MolMed's Included Lung Cancer Pipeline and Competitive Fall-Out 1155

Table 197: Mologen's Included Lung Cancer Pipeline and Competitive Fall-Out 1157

Table 198: Mycenax's Included Lung Cancer Pipeline and Competitive Fall-Out 1159

Table 199: Nektar Therapeutics'Included Lung Cancer Pipeline and Competitive Fall-Out 1160

Table 200: Nereus Pharmaceuticals'Included Lung Cancer Pipeline and Competitive Fall-Out 1162

Table 201: Nerviano Medical Sciences'Included Lung Cancer Pipeline and Competitive Fall-Out 1163

Table 202: Neurocrine Biosciences'Included Lung Cancer Pipeline and Competitive Fall-Out 1165

Table 203: NewSouth Innovations'Included Lung Cancer Pipeline and Competitive Fall-Out 1166

Table 204: Nippon Kayaku's Included Lung Cancer Pipeline and Competitive Fall-Out 1167

Table 205: Nippon Shinyaku's Included Lung Cancer Pipeline and Competitive Fall-Out 1169

Table 206: Non-industrial source's In

To order this report:

Drug and Medication Industry: Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com